# US 11,299,750 B2 · Cultured transgenic cell allowing growth of norovirus, and use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,299,750 B2 - Document ID: US11299750B2 - Status: Granted - Kind: B2 - Application number: 16/074,648 - Filed: 2017-02-01 - Published: 2019-02-07 - Granted: 2022-04-12 - Earliest claimed: 2016-02-03 - Assignees: Director-General of National Institute of Infectious Diseases; Denka Company Limited; National Center for Geriatrics and Gerontology - Applicants: Japan AS Represented By Director-General of National Institute of Infectious Diseases; Denka Company Limited; National Center for Geriatrics and Gerontology - Inventors: Kei Haga; Akira Fujimoto; Reiko Todaka; Kazuhiko Katayama; Akira Nakanishi; Motohiro Miki; Sakari Sekine; Hiroshi Otsuka; Shigetaka Mimori - Web page: https://patentgrep.com/patent/US11299750B2 ## CPC - C12N 15/86: Viral vectors - C07K 14/005: from viruses - C07K 14/70503: {Immunoglobulin superfamily} - C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS} - C12N 7/02: Recovery or purification - C12Q 1/02: involving viable microorganisms - G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q) - G01N 33/5088: {of vertebrates} - G01N 2333/08: RNA viruses - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract An object of the present invention is to solve problems in terms of stagnation of research on norovirus by providing a cultured transgenic cell or a transgenic animal in which murine norovirus (MNV) can be grown across the barrier of host specificity in mammalian cells, and providing a screening method that uses the cultured transgenic cell or the transgenic animal. The present inventors have found that MNV infection is determined in a cultured transgenic mammalian cell or a mammal possessing the cultured transgenic mammalian cell as its own cell, the cultured transgenic mammalian cell containing one or more species selected from the entirety or a portion of the murine CD300F gene and/or a CD300 family gene having an extracellular domain nucleotide sequence similar to that of the murine CD300F gene. The present inventors have solved the aforementioned problems by providing, for example, a norovirus-related drug screening method on the basis of this finding. ## Claims ### Claim 1 A cultured transgenic mammalian cell, wherein said cell comprises a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence having 80% or more sequence identity to residues 31-137 of SEQ ID NO: 2, and wherein the cell is infected with murine norovirus. ### Claim 2 (depends on 1) The cultured transgenic mammalian cell according to claim 1, wherein said polypeptide contains all β-coil structure domains that the polypeptide of SEQ ID NO: 2 does. ### Claim 3 (depends on 1) The cultured transgenic mammalian cell according to claim 1, wherein said polypeptide contains a transmembrane domain. ### Claim 4 (depends on 3) The cultured transgenic mammalian cell according to claim 3, wherein said polypeptide contains an intracellular domain having a signaling function. ### Claim 5 (depends on 1) The cultured transgenic mammalian cell according to claim 1, wherein said polypeptide comprises the extracellular domain of murine CD300d or murine CD300f, wherein said murine CD300d has the amino acid sequence of SEQ ID NO: 6, and wherein said murine CD300f has the amino acid sequence of SEQ ID NO: 2. ### Claim 6 (depends on 3) The cultured transgenic mammalian cell according to claim 3, wherein said polypeptide does not contain an intracellular domain having a signaling function. ### Claim 7 (depends on 1) The cultured transgenic mammalian cell according to claim 1, wherein said nucleotide sequence encodes a polypeptide comprising residues 1-150 of SEQ ID NO: 2. ### Claim 8 (depends on 1) The cultured transgenic mammalian cell according to claim 1, wherein the cultured mammalian cell is a cultured cell line, an organoid derived from a biopsy sample, an immortalized cell, or an iPS cell. ### Claim 9 (depends on 1) The cultured transgenic mammalian cell according to claim 1, wherein the cultured mammalian cell is a human cell, a mouse cell, a rat cell, a hamster cell, a guinea pig cell, a rabbit cell, a cat cell, a dog cell, a pig cell, or a monkey cell. ### Claim 10 (depends on 9) The cultured transgenic mammalian cell according to claim 9, wherein the cultured mammalian cell is an HEK293T cell, a Caco2 cell, an Intestine407 cell, a cultured macrophagic 15310-LN cell, an NALM-6 cell, an RAW264.7 cell, an NIH3T3 cell, an M1 cell, a BHK cell, a CHO cell, a CRFK cell, a MDCK cell, a PK-15 cell, a VERO cell, or a COS7 cell.